This article is more than 5 years old. Information may no longer be current.

Ista to begin phase 3 study on bromfenac

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — A twice-daily anti-inflammatory drug for the treatment of ocular inflammation following cataract surgery will begin phase 3 trials shortly, according to the drug’s manufacturer.

Ista Pharmaceuticals, developers of bromfenac, believes the drug’s twice-daily dosing will help with patient compliance. Currently, other non-steroidal anti-inflammatory drugs approved for the same indication are dosed four times daily.

Executives with the company expect clinical trials to be completed by the end of the year, with a possible U.S. approval by 2005. The drug is approved for the treatment of ocular inflammation in Japan. Senju Pharmaceuticals is the original developer and marketer of bromfenac. Ista has all commercial rights to the compound here in the United States.